Yu, Zhinuan
Celgene (United States)
8 papers on CoChat
Most cited papers
- Verified
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine
Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors
Cited by 1,450
- Verified
Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine
Multiple Myeloma Research and TreatmentsBone health and treatments
Cited by 1,233
- Verified
Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis
McCarthy, P. L., Holstein, S. A., Petrucci, M. T., Richardson, P. G., Hulin, C., Tosi, P., Bringhen, S., Musto, P., Anderson, K. C., Caillot, D., et al. (2017) · Journal of Clinical Oncology
Multiple Myeloma Research and TreatmentsBone health and treatments
Cited by 698
- Verified
Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma
Walker, B. A., Mavrommatis, K., Wardell, C. P., Ashby, T. C., Bauer, M., Davies, F. E., Rosenthal, A., Wang, H., Qu, P., Hoering, A., et al. (2018) · Blood
Multiple Myeloma Research and TreatmentsAcute Myeloid Leukemia Research
Cited by 475
- Verified
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study
Richardson, P. G., Siegel, D. S., Vij, R., Hofmeister, C. C., Baz, R., Jagannath, S., Chen, C., Lonial, S., Jakubowiak, A., Bahlis, N., et al. (2014) · Blood
Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors
Cited by 381
- Verified
Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure
Wang, M., Dimopoulos, M. A., Chen, C., Cibeira, M. T., Attal, M., Spencer, A., Rajkumar, S. V., Yu, Z., Olesnyckyj, M., Zeldis, J. B., et al. (2008) · Blood
Multiple Myeloma Research and TreatmentsBone health and treatments
Cited by 176
- Verified
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma
Palumbo, A., Gay, F., Cavallo, F., Di Raimondo, F., Larocca, A., Hardan, I., Nagler, A., Petrucci, M. T., Hajek, R., Pezzatti, S., et al. (2015) · Journal of Clinical Oncology
Multiple Myeloma Research and TreatmentsBone health and treatments
Cited by 150
- Verified
Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): A meta-analysis (MA) of overall survival (OS).
Attal, M., Palumbo, A., Holstein, S. A., Lauwers-Cances, V., Petrucci, M. T., Richardson, P. G., Hulin, C., Tosi, P., Anderson, K. C., Caillot, D., et al. (2016) · Journal of Clinical Oncology
Multiple Myeloma Research and TreatmentsBone health and treatments
Cited by 63
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free